Trevena, Inc.

212 articles with Trevena, Inc.

• Trevena Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 Patients

  4/21/2021

  -- REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19 Interim review of Imperial College London TRV027 study data supports transition to larger study

• Trevena, Inc. Announces Presentations of OLINVYK™ Health Economic Models at AMCP 2021 Annual Meeting

  4/15/2021

  Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the AMCP 2021 Annual Meeting.

• Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results

  3/9/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, reported its financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of its 2020 and 2021 year-to-date operational highlights.

• Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

  3/5/2021

  Trevena to host conference call on March 9 th , 2021, at 8:00 a.m. ET --

• Trevena, Inc. to Participate in March 2021 Virtual Investor Conferences

  3/1/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that management will participate in two upcoming virtual investor conferences in March.

• Trevena, Inc. to Present at the 10th Annual SVB Leerink Global Healthcare Conference

  2/22/2021

  Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will present a corporate update at the 10 th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:40 a.m. EST.

• Trevena, Inc. Announces Publication Highlighting OLINVYK™ Respiratory Safety Data in High-Risk Patients in Pain & Therapy

  1/28/2021

  Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of a new analysis of respiratory safety data from the OLINVYK Phase 3 multi-site “real world” safety study in Pain and Therapy.

• Trevena, Inc. to Participate in Two Upcoming Virtual Investor Conferences

  1/7/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that management will participate in two upcoming virtual investor conferences, with additional details below.

• Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) injection in Pain and Therapy

  11/20/2020

  Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication, titled “Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials,” with lead author Tim Beard,

• Trevena, Inc. to Participate in the Following November Virtual 2020 Investor Conferences

  11/9/2020

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that management will participate in the following conferences in the month of November and invites investors to participate by webcast.

• Trevena, Inc. Announces Three OLINVYK™ Presentations at the Virtual American Society of Anesthesiologists 2020 Annual Meeting

  10/5/2020

  Posters highlight improvements in respiratory safety and gastrointestinal tolerability associated with OLINVYK (oliceridine) injection vs. IV morphine

• Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting

  9/21/2020

  Live presentation highlightingTRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clotting

• Trevena, Inc. to Present at September 2020 Virtual Investor Conferences

  9/2/2020

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast.

• Trevena Announces Publications of OLINVYK™ Respiratory Safety Analyses vs. IV Morphine

  8/26/2020

  Publication in Anesthesiology: Favorable benefit-risk profile for OLINVYK (oliceridine) injection as measured by clinical utility function analysis

• Trevena Announces Initiation of TRV027 Study in COVID-19 Patients in Collaboration With Imperial College London

  8/24/2020

  TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19

• Trevena Announces Receipt of Milestone Payment Under Partnership in China With Jiangsu Nhwa Pharmaceutical Co.

  8/20/2020

  -- $3 million milestone payment for U.S. approval of OLINVYK™ (oliceridine) injection Additional approval and commercialization milestone payments expected as well as 10% royalties on net sales in China -- CHESTERBROOK, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it has a received a $3

• Trevena to Present at the Virtual JMP Securities CNS Forum

  8/14/2020

  Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Officer, will participate in a fireside chat at the JMP Securities CNS Forum, being held virtually on August 19 - 20, 2020. Presentation Details Date:   Thursday, August 20, 2020 Time: 

• 

  FDA Approves Trevena's IV Opioid for Short-Term Acute Pain Management

  8/13/2020

  Olinvyk is indicated for short-term intravenous use in hospitals or other controlled clinical settings, such as during inpatient and outpatient procedures.

• Trevena Announces Pricing of $50 Million Public Offering of Common Stock

  8/12/2020

  Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (“CNS”) disorders, announced today the pricing of its previously announced underwritten public offering of 21,739,131 shares of its common stock at a public offering price of $2.30 per share. Trevena has also granted the underwriters a 30-day opti

• Trevena Announces Proposed Public Offering of Common Stock - Aug 11, 2020

  8/11/2020

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.